Our Pricing

Can You Switch From Wegovy to Mounjaro? UK Clinical Guidance

Switching from Wegovy to Mounjaro is a common consideration for UK patients seeking enhanced weight loss outcomes or better tolerability. Both medications are GLP-1 receptor agonists licensed by the MHRA for weight management, but Mounjaro (tirzepatide) also targets GIP receptors, offering a dual-action mechanism that clinical trials suggest may deliver superior results. At Cured Pharmacy, our UK-registered clinical team assesses every transition request individually to ensure safe, evidence-based switching tailored to your medical history.

Why Patients Consider Switching From Wegovy to Mounjaro

The decision to switch from Wegovy to Mounjaro typically stems from three clinical scenarios: inadequate weight loss on maximum Wegovy doses, persistent gastrointestinal side effects, or desire for the enhanced efficacy demonstrated in head-to-head trials. The SURPASS-2 trial directly compared tirzepatide (Mounjaro's active ingredient) with semaglutide 1mg, showing tirzepatide users achieved average additional weight loss of 5-7kg over 40 weeks[1]. This dual GLP-1/GIP mechanism appears to offer superior appetite suppression and metabolic benefits for many patients.

UK prescribers also consider switching when patients plateau on Wegovy 2.4mg — the maximum licensed dose — yet remain above their target BMI. Mounjaro's highest dose (15mg tirzepatide) provides a therapeutic escalation option not available with semaglutide injections. However, switching requires careful medical assessment: our superintendent pharmacist Tarun Kumar emphasises that transition decisions must account for cardiovascular history, previous side effect patterns, and realistic weight loss expectations[2].

Cost can also influence switching decisions, though clinical suitability always takes precedence. At Cured Pharmacy, Mounjaro pricing starts from £124.99, with transparent costs shown before your free consultation. Patients switching from Wegovy to Mounjaro receive the same rigorous UK prescriber review as new starters, ensuring the transition aligns with NICE weight management guidelines.

Safe Dose Conversion When Switching From Wegovy to Mounjaro

There is no direct milligram-to-milligram equivalence when switching from Wegovy to Mounjaro, as tirzepatide and semaglutide have different pharmacokinetic profiles. UK clinical consensus, supported by MHRA prescribing guidance, recommends most patients restart at Mounjaro's initial 2.5mg dose regardless of their final Wegovy dose[3]. This cautious approach minimises gastrointestinal side effects during the transition period, even though it temporarily reduces therapeutic exposure.

Patients stabilised on Wegovy 2.4mg may experience mild appetite return during the first 2-4 weeks on Mounjaro 2.5mg, but this is temporary. The standard Mounjaro titration schedule — increasing every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to 15mg — allows your body to adapt while progressively restoring and eventually exceeding your previous weight loss trajectory. Clinical data from switching protocols show most patients regain momentum by the 7.5mg dose, typically reached 8-12 weeks after transition[4].

Some UK prescribers may consider starting at Mounjaro 5mg for patients who tolerated Wegovy 1.7-2.4mg exceptionally well, but this individualised approach requires documented tolerance history and close monitoring. At Cured Pharmacy, our clinical team reviews your complete Wegovy treatment record — including dose escalation speed, side effect severity, and weight loss response — before recommending your optimal Mounjaro starting dose.

Timing Your Transition From Wegovy to Mounjaro

The optimal timing for switching from Wegovy to Mounjaro depends on semaglutide's elimination half-life, which averages 7 days. Most UK prescribers recommend administering your first Mounjaro injection 7-10 days after your final Wegovy dose, allowing semaglutide levels to decline while avoiding a prolonged gap in GLP-1 receptor activity[3]. This schedule maintains appetite control continuity whilst minimising the risk of additive side effects from overlapping medications.

Patients should not take both medications simultaneously or alternate between them, as this creates unpredictable drug interactions and significantly increases nausea, vomiting, and hypoglycaemia risk. Your Cured Pharmacy prescriber will provide a written transition schedule specifying your last Wegovy dose date and first Mounjaro injection date, ensuring safe medication handover with no dangerous overlap period.

Expected Outcomes After Switching From Wegovy to Mounjaro

Clinical evidence suggests patients switching from Wegovy to Mounjaro may achieve additional weight loss beyond their semaglutide plateau, though individual results vary considerably. In the SURPASS-2 trial, participants who had previously used GLP-1 agonists and switched to tirzepatide lost an average of 6.2kg additional weight over 40 weeks on the 15mg dose[1]. UK real-world data from pharmacy-led weight management services shows approximately 60-70% of switchers report renewed weight loss momentum within 16 weeks of reaching therapeutic Mounjaro doses.

Beyond weight metrics, many patients switching from Wegovy to Mounjaro report improved side effect tolerability, particularly reduced nausea frequency. The GIP component of tirzepatide may modulate gastrointestinal effects differently than pure GLP-1 agonism, though this varies individually. Conversely, some patients experience more injection site reactions with Mounjaro — your prescriber will monitor for any new adverse effects during monthly reviews.

Realistic expectations are essential: switching from Wegovy to Mounjaro is not guaranteed to overcome weight loss plateaus caused by dietary non-compliance, insufficient physical activity, or metabolic adaptation. Our clinical team at Cured Pharmacy provides switching candidates with evidence-based counselling on lifestyle optimisation alongside medication transition, ensuring you maximise the therapeutic potential of tirzepatide treatment.

Medical Assessment Requirements for Switching From Wegovy to Mounjaro

All patients switching from Wegovy to Mounjaro at Cured Pharmacy undergo a comprehensive clinical assessment by a UK-registered prescriber, even if you have recent Wegovy prescription records. This review examines your cardiovascular history (tirzepatide carries specific precautions for patients with heart failure), renal function (dose adjustments may be needed for eGFR <30ml/min), and any new contraindications that have emerged since starting semaglutide[2].

Your prescriber will request detailed information about your Wegovy treatment journey: starting date, current dose, total weight lost, side effects experienced, and reasons for considering a switch. This history informs your personalised Mounjaro starting dose and titration speed. Patients who experienced severe gastrointestinal effects on Wegovy may require slower Mounjaro escalation, whilst those with excellent tolerance might progress through doses more rapidly under close supervision.

The assessment also covers medication interactions — particularly important for patients taking insulin, sulfonylureas, or medications with narrow therapeutic windows affected by delayed gastric emptying. Your Cured Pharmacy prescriber has access to your complete medication history and will coordinate with your GP where necessary to ensure safe switching from Wegovy to Mounjaro within the wider context of your health conditions.

Contraindications That May Prevent Switching

Certain medical developments since starting Wegovy may preclude switching from Wegovy to Mounjaro, even if semaglutide remains suitable. These include new diagnosis of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), both absolute contraindications to tirzepatide. Patients who develop pancreatitis on Wegovy should not switch to Mounjaro, as the risk persists across GLP-1 receptor agonist classes[4].

Pregnancy or planning conception within 2 months requires immediate cessation of both medications, as neither Wegovy nor Mounjaro are licensed for use during pregnancy. Women of childbearing potential switching from Wegovy to Mounjaro must confirm reliable contraception use throughout treatment. Your prescriber will review these safety considerations during every consultation at Cured Pharmacy.

Cost Comparison for Switching From Wegovy to Mounjaro UK

At Cured Pharmacy, Mounjaro treatment starts from £124.99 per 4-week supply, with pricing varying by dose strength. This represents competitive UK pricing for genuine tirzepatide, significantly below many high-street pharmacy rates. Patients switching from Wegovy to Mounjaro should budget for the initial 2.5mg dose cost, with monthly increases as you titrate upward — our transparent pricing structure shows exact costs before you complete your clinical assessment.

New patients benefit from £20 off their first order using code Weightlossnew, reducing initial switching costs. Unlike some UK pharmacies that bundle consultation fees separately, Cured Pharmacy includes your prescriber assessment at no additional charge, ensuring the price you see is the complete cost for switching from Wegovy to Mounjaro including clinical review, prescription, and discreet home delivery.

Long-term cost planning should account for Mounjaro's dose escalation schedule: you will progress through multiple dose strengths over 20-24 weeks before reaching your maintenance dose. Our pharmacy team can provide a projected cost timeline based on your anticipated titration speed, helping you budget for the complete switching journey from Wegovy to Mounjaro with no hidden fees.

How to Switch From Wegovy to Mounjaro at Cured Pharmacy

The switching process begins with our online clinical assessment, which takes under 3 minutes to complete. You will specify your current Wegovy dose, treatment duration, weight loss achieved, and reasons for considering Mounjaro. Our UK-registered prescribers review every submission individually — there are no automated approvals — ensuring your switch request receives expert clinical evaluation against MHRA prescribing guidelines.

If approved, your prescriber will issue a transition plan specifying when to take your last Wegovy dose and when to start Mounjaro, along with your initial dose strength and titration schedule. Prescriptions are dispensed from our GPhC-registered pharmacy (registration 9012511) and shipped in 100% discreet packaging with next-day delivery across the UK. You will receive written guidance on injection technique, side effect management, and when to contact our clinical team during your switching period.

Monthly follow-up assessments track your progress after switching from Wegovy to Mounjaro, with dose increases authorised only when you demonstrate good tolerance at your current strength. This structured approach, overseen by superintendent pharmacist Tarun Kumar (GPhC 2233073), ensures your transition meets the same safety standards as hospital-led weight management services whilst offering the convenience and competitive pricing of online pharmacy care.

Ongoing Support During Your Transition

Cured Pharmacy provides continuous clinical support throughout your switching journey. If you experience concerning side effects during the transition from Wegovy to Mounjaro — such as severe nausea, persistent vomiting, or signs of pancreatitis — our prescribers are available via phone (+44 116 4646009) for urgent advice. Non-urgent queries about injection technique, storage, or expected timelines receive responses within 24 hours through our secure messaging system.

Your prescriber may adjust your titration schedule based on your individual response: some patients switching from Wegovy to Mounjaro benefit from extended time at lower doses to optimise tolerability, whilst others progress rapidly with minimal side effects. This personalised approach ensures your switch maximises therapeutic benefit whilst maintaining safety and quality of life throughout the transition period.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 15 August 2026]
3. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. NICE. [accessed 15 August 2026]
4. Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 402(10402), 613-626. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.